News

Please join us on January 21st, 2023 from 12:00 pm - 3:00 pm ET for our next webinar on ATTRv and ATTRwt Amyloidosis. Our speakers include Cardiologist Mathew…

Prothena Presents Data Demonstrating Consistent Survival Benefit Observed with Birtamimab in Mayo Stage IV AL Amyloidosis Patients in Phase 3 VITAL Study at ASH 2022

The ASG has been holding this biennial support meeting since 2009. We expect more than 400 patients and caregivers. We will have amyloidosis researchers and…

Please join us on October 29th, 2022 from 12:00 pm - 3:00 pm ET for our next webinar on AL Amyloidosis. Our speakers include: Hematologists Dr. Morie Gertz-Mayo…

Sami L. Khella, MDexternal link, opens in a new tab and Shawna Feely, MS, LGC will join us for a one-hour program on hereditary neuropathies and the benefits of…

UC San Diego Health is first in the nation to offer a new injectable medication to patients with nerve damage caused by hereditary transthyretin amyloidosis, a rare…

AL amyloidosis is a life-threatening disease related to bone marrow cancer, multiple myeloma. It is caused when a person's antibody-producing white blood cells (i.e…

Please join us on July 23rd from 12:00 pm - 3:00 pm ET for our next webinar on ATTRv and ATTRwt Amyloidosis. Our speakers include Cardiologists, Neurologists and…

Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed…

Attralus, Inc., a clinical stage biopharmaceutical company developing transformative medicines to improve the lives of patients with systemic amyloidosis, announced…